Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes: A Decision Analysis
Objective. The authors developed a Markov decision model to evaluate the health implications of testing for mutations in the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Prophylactic measures considered included various combinations of immediate and delayed bilateral mastectomy and oo...
Gespeichert in:
| Veröffentlicht in: | Medical decision making 1998-10, Vol.18 (4), p.365-375 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 375 |
|---|---|
| container_issue | 4 |
| container_start_page | 365 |
| container_title | Medical decision making |
| container_volume | 18 |
| creator | Tengs, Tammy O. Winer, Eric P. Paddock, Susan Aguilar-Chavez, Omar Berry, Donald A. |
| description | Objective. The authors developed a Markov decision model to evaluate the health implications of testing for mutations in the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Prophylactic measures considered included various combinations of immediate and delayed bilateral mastectomy and oophorectomy or taking no action. Methods. The model incorporated the likelihood of developing breast and/or ovarian cancer, survival, and quality of life. Parameter values were taken from public data bases, the published literature, and a survey of cancer experts. Outcomes considered were additional life expectancy and quality-adjusted life years (QALYs). Results are reported for 30-year-old cancer-free women at various levels of hereditary risk. Results and conclusions. The vast majority of women will not benefit from testing because their pre-test risks are low and surgical prophylaxis is undesirable. However, women who have family histories of early breast and/or ovarian cancer may gain up to 2 QALYs by allowing genetic testing to inform their decisions. Key words: BRCA1; BRCA2; ge netic testing; breast cancer; ovarian cancer; decision analysis. (Med Decis Making 1998;18:365-375) |
| doi_str_mv | 10.1177/0272989X9801800402 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_744615050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0272989X9801800402</sage_id><sourcerecordid>744615050</sourcerecordid><originalsourceid>FETCH-LOGICAL-c349t-ac9af80b84b3ca54667ff9ee426f0c6108952cf2d0697c8879fe873cf00f5db13</originalsourceid><addsrcrecordid>eNp90U9LwzAYBvAgipvTL-BBigc91b1J0_w5bkOnMhjohN1Kmiazo2tn0gr79nZuoCjslBx-75M3PAhdYrjDmPM-EE6kkHMpAAsACuQIdXEck5AJPD9G3S0It6KDzrxfAmAqBT1FHQwRJzEXXfQ8M77Oy0VgKxfU7yYYvowGOFBl9n0jwdAZ5etw-qlcrspgpEptXPDaeG3WdZ7mRV5vgrEpjT9HJ1YV3lzszx56e7ifjR7DyXT8NBpMQh1RWYdKS2UFpIKmkVYxZYxbK42hhFnQDIOQMdGWZMAk10JwaY3gkbYANs5SHPXQ7S537aqPpl0_WeXtNkWhSlM1PuGUMhxDDK28OSiZJFQwJlp4_Qcuq8aV7S8SQiIhOUSyRWSHtKu8d8Yma5evlNskGJJtIcn_Qtqhq31yk65M9mtk10AL-jvg1cL8PHsg8gsSPZC8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223897039</pqid></control><display><type>article</type><title>Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes: A Decision Analysis</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Tengs, Tammy O. ; Winer, Eric P. ; Paddock, Susan ; Aguilar-Chavez, Omar ; Berry, Donald A.</creator><creatorcontrib>Tengs, Tammy O. ; Winer, Eric P. ; Paddock, Susan ; Aguilar-Chavez, Omar ; Berry, Donald A.</creatorcontrib><description>Objective. The authors developed a Markov decision model to evaluate the health implications of testing for mutations in the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Prophylactic measures considered included various combinations of immediate and delayed bilateral mastectomy and oophorectomy or taking no action. Methods. The model incorporated the likelihood of developing breast and/or ovarian cancer, survival, and quality of life. Parameter values were taken from public data bases, the published literature, and a survey of cancer experts. Outcomes considered were additional life expectancy and quality-adjusted life years (QALYs). Results are reported for 30-year-old cancer-free women at various levels of hereditary risk. Results and conclusions. The vast majority of women will not benefit from testing because their pre-test risks are low and surgical prophylaxis is undesirable. However, women who have family histories of early breast and/or ovarian cancer may gain up to 2 QALYs by allowing genetic testing to inform their decisions. Key words: BRCA1; BRCA2; ge netic testing; breast cancer; ovarian cancer; decision analysis. (Med Decis Making 1998;18:365-375)</description><identifier>ISSN: 0272-989X</identifier><identifier>EISSN: 1552-681X</identifier><identifier>DOI: 10.1177/0272989X9801800402</identifier><identifier>PMID: 10372578</identifier><identifier>CODEN: MDMADE</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Aged ; Breast Neoplasms - epidemiology ; Breast Neoplasms - genetics ; Breast Neoplasms - prevention & control ; Decision Support Techniques ; Female ; Genes, BRCA1 - physiology ; Genes, Tumor Suppressor - physiology ; Genetic Predisposition to Disease ; Genetic Testing ; Humans ; Incidence ; Markov Chains ; Mastectomy ; Middle Aged ; Ovarian cancer ; Ovarian Neoplasms - epidemiology ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - prevention & control ; Ovariectomy ; Predictive Value of Tests ; Quality-Adjusted Life Years ; Risk Assessment - methods ; Survival Analysis ; United States - epidemiology</subject><ispartof>Medical decision making, 1998-10, Vol.18 (4), p.365-375</ispartof><rights>Copyright Hanley & Belfus, Inc. Oct-Dec 1998</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c349t-ac9af80b84b3ca54667ff9ee426f0c6108952cf2d0697c8879fe873cf00f5db13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0272989X9801800402$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0272989X9801800402$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21819,27924,27925,43621,43622</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10372578$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tengs, Tammy O.</creatorcontrib><creatorcontrib>Winer, Eric P.</creatorcontrib><creatorcontrib>Paddock, Susan</creatorcontrib><creatorcontrib>Aguilar-Chavez, Omar</creatorcontrib><creatorcontrib>Berry, Donald A.</creatorcontrib><title>Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes: A Decision Analysis</title><title>Medical decision making</title><addtitle>Med Decis Making</addtitle><description>Objective. The authors developed a Markov decision model to evaluate the health implications of testing for mutations in the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Prophylactic measures considered included various combinations of immediate and delayed bilateral mastectomy and oophorectomy or taking no action. Methods. The model incorporated the likelihood of developing breast and/or ovarian cancer, survival, and quality of life. Parameter values were taken from public data bases, the published literature, and a survey of cancer experts. Outcomes considered were additional life expectancy and quality-adjusted life years (QALYs). Results are reported for 30-year-old cancer-free women at various levels of hereditary risk. Results and conclusions. The vast majority of women will not benefit from testing because their pre-test risks are low and surgical prophylaxis is undesirable. However, women who have family histories of early breast and/or ovarian cancer may gain up to 2 QALYs by allowing genetic testing to inform their decisions. Key words: BRCA1; BRCA2; ge netic testing; breast cancer; ovarian cancer; decision analysis. (Med Decis Making 1998;18:365-375)</description><subject>Adult</subject><subject>Aged</subject><subject>Breast Neoplasms - epidemiology</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - prevention & control</subject><subject>Decision Support Techniques</subject><subject>Female</subject><subject>Genes, BRCA1 - physiology</subject><subject>Genes, Tumor Suppressor - physiology</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetic Testing</subject><subject>Humans</subject><subject>Incidence</subject><subject>Markov Chains</subject><subject>Mastectomy</subject><subject>Middle Aged</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - epidemiology</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - prevention & control</subject><subject>Ovariectomy</subject><subject>Predictive Value of Tests</subject><subject>Quality-Adjusted Life Years</subject><subject>Risk Assessment - methods</subject><subject>Survival Analysis</subject><subject>United States - epidemiology</subject><issn>0272-989X</issn><issn>1552-681X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90U9LwzAYBvAgipvTL-BBigc91b1J0_w5bkOnMhjohN1Kmiazo2tn0gr79nZuoCjslBx-75M3PAhdYrjDmPM-EE6kkHMpAAsACuQIdXEck5AJPD9G3S0It6KDzrxfAmAqBT1FHQwRJzEXXfQ8M77Oy0VgKxfU7yYYvowGOFBl9n0jwdAZ5etw-qlcrspgpEptXPDaeG3WdZ7mRV5vgrEpjT9HJ1YV3lzszx56e7ifjR7DyXT8NBpMQh1RWYdKS2UFpIKmkVYxZYxbK42hhFnQDIOQMdGWZMAk10JwaY3gkbYANs5SHPXQ7S537aqPpl0_WeXtNkWhSlM1PuGUMhxDDK28OSiZJFQwJlp4_Qcuq8aV7S8SQiIhOUSyRWSHtKu8d8Yma5evlNskGJJtIcn_Qtqhq31yk65M9mtk10AL-jvg1cL8PHsg8gsSPZC8</recordid><startdate>19981001</startdate><enddate>19981001</enddate><creator>Tengs, Tammy O.</creator><creator>Winer, Eric P.</creator><creator>Paddock, Susan</creator><creator>Aguilar-Chavez, Omar</creator><creator>Berry, Donald A.</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>19981001</creationdate><title>Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes</title><author>Tengs, Tammy O. ; Winer, Eric P. ; Paddock, Susan ; Aguilar-Chavez, Omar ; Berry, Donald A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c349t-ac9af80b84b3ca54667ff9ee426f0c6108952cf2d0697c8879fe873cf00f5db13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Breast Neoplasms - epidemiology</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - prevention & control</topic><topic>Decision Support Techniques</topic><topic>Female</topic><topic>Genes, BRCA1 - physiology</topic><topic>Genes, Tumor Suppressor - physiology</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetic Testing</topic><topic>Humans</topic><topic>Incidence</topic><topic>Markov Chains</topic><topic>Mastectomy</topic><topic>Middle Aged</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - epidemiology</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - prevention & control</topic><topic>Ovariectomy</topic><topic>Predictive Value of Tests</topic><topic>Quality-Adjusted Life Years</topic><topic>Risk Assessment - methods</topic><topic>Survival Analysis</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tengs, Tammy O.</creatorcontrib><creatorcontrib>Winer, Eric P.</creatorcontrib><creatorcontrib>Paddock, Susan</creatorcontrib><creatorcontrib>Aguilar-Chavez, Omar</creatorcontrib><creatorcontrib>Berry, Donald A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Medical decision making</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tengs, Tammy O.</au><au>Winer, Eric P.</au><au>Paddock, Susan</au><au>Aguilar-Chavez, Omar</au><au>Berry, Donald A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes: A Decision Analysis</atitle><jtitle>Medical decision making</jtitle><addtitle>Med Decis Making</addtitle><date>1998-10-01</date><risdate>1998</risdate><volume>18</volume><issue>4</issue><spage>365</spage><epage>375</epage><pages>365-375</pages><issn>0272-989X</issn><eissn>1552-681X</eissn><coden>MDMADE</coden><abstract>Objective. The authors developed a Markov decision model to evaluate the health implications of testing for mutations in the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes. Prophylactic measures considered included various combinations of immediate and delayed bilateral mastectomy and oophorectomy or taking no action. Methods. The model incorporated the likelihood of developing breast and/or ovarian cancer, survival, and quality of life. Parameter values were taken from public data bases, the published literature, and a survey of cancer experts. Outcomes considered were additional life expectancy and quality-adjusted life years (QALYs). Results are reported for 30-year-old cancer-free women at various levels of hereditary risk. Results and conclusions. The vast majority of women will not benefit from testing because their pre-test risks are low and surgical prophylaxis is undesirable. However, women who have family histories of early breast and/or ovarian cancer may gain up to 2 QALYs by allowing genetic testing to inform their decisions. Key words: BRCA1; BRCA2; ge netic testing; breast cancer; ovarian cancer; decision analysis. (Med Decis Making 1998;18:365-375)</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>10372578</pmid><doi>10.1177/0272989X9801800402</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0272-989X |
| ispartof | Medical decision making, 1998-10, Vol.18 (4), p.365-375 |
| issn | 0272-989X 1552-681X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_744615050 |
| source | Access via SAGE; MEDLINE |
| subjects | Adult Aged Breast Neoplasms - epidemiology Breast Neoplasms - genetics Breast Neoplasms - prevention & control Decision Support Techniques Female Genes, BRCA1 - physiology Genes, Tumor Suppressor - physiology Genetic Predisposition to Disease Genetic Testing Humans Incidence Markov Chains Mastectomy Middle Aged Ovarian cancer Ovarian Neoplasms - epidemiology Ovarian Neoplasms - genetics Ovarian Neoplasms - prevention & control Ovariectomy Predictive Value of Tests Quality-Adjusted Life Years Risk Assessment - methods Survival Analysis United States - epidemiology |
| title | Testing for the BRCA1 and BRCA2 Breast-Ovarian Cancer Susceptibility Genes: A Decision Analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T13%3A29%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Testing%20for%20the%20BRCA1%20and%20BRCA2%20Breast-Ovarian%20Cancer%20Susceptibility%20Genes:%20A%20Decision%20Analysis&rft.jtitle=Medical%20decision%20making&rft.au=Tengs,%20Tammy%20O.&rft.date=1998-10-01&rft.volume=18&rft.issue=4&rft.spage=365&rft.epage=375&rft.pages=365-375&rft.issn=0272-989X&rft.eissn=1552-681X&rft.coden=MDMADE&rft_id=info:doi/10.1177/0272989X9801800402&rft_dat=%3Cproquest_cross%3E744615050%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223897039&rft_id=info:pmid/10372578&rft_sage_id=10.1177_0272989X9801800402&rfr_iscdi=true |